secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2022-04-25T23:59:59+00:00
Accession:  0001213900-22-021411
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar announces strategic reorganization, 70% workforce reduction, cash runway to H1 2025
--------------------------------------------------------------------------------

- Workforce reduced by ~70%; expects charge of $150-160M in Q2 2022.
- Cash runway extended into first half of 2025; Q1 2022 cash & investments ~$704M.
- CMO Dr. Dimitry Nuyten stepping down; Dr. Brian Kotzin to succeed.
- CCO John Northcott to depart June 2022; remains as strategic advisor through 2022.
- Preliminary Q1 revenue ~$25M; R&D expense ~$110M; gain of ~$33M from SFJ derivative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390022021411/0001213900-22-021411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390022021411/ea158792-8k_nektarthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-021411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer